Generic drug
Metformin / sitagliptin price, strengths & recalls
Pharmacies pay $75.28 for 30 tablets of Metformin / sitagliptin 1000 mg / 50 mg tablet this week, and from $75.28 to $250.28 across its 5 priced strengths and forms. 3 manufacturers make it. It has 1 recall on record, none ongoing. Its official label last changed on October 12, 2026.
Generic- Fair cash price
- $97.07
- Strengths
- 5
- Makers
- 3
- Updated
- Nov 11
Metformin / sitagliptin price by strength
What pharmacies pay for each strength and form this week (Nov 11, 2026), for 30 tablets. Choose one for its fair price, 52-week chart and makers.
| Strength and form | Per unit | Pharmacies pay |
|---|---|---|
| 500 mg / 50 mg (24 hr) extended-release tablet | $3.74 | $112.19 / 30 tablets |
| 1000 mg / 100 mg (24 hr) extended-release tablet | $8.34 | $250.28 / 30 tablets |
| 1000 mg / 50 mg (24 hr) extended-release tablet | $4.18 | $125.34 / 30 tablets |
| 500 mg / 50 mg tablet | $2.51 | $75.44 / 30 tablets |
| 1000 mg / 50 mg tablet | $2.51 | $75.28 / 30 tablets |
The lowest cost per tablet is 1000 mg / 50 mg tablet at $2.51. Strengths aren't interchangeable - ask your pharmacist or prescriber before changing.
Brand names of metformin / sitagliptin
A brand and its generic share the active ingredient; the generic is almost always far cheaper.
Medicare negotiated price
Medicare negotiated a maximum fair price of $80.00 for a 30-day supply of Janumet / Janumet XR, against a 2024 list price of $526.00. It takes effect on January 1, 2027.
What this means for patients
- The negotiated price is what Medicare Part D plans pay for the drug - not your price at the counter.
- What you pay depends on your plan's copay or coinsurance and where you are in the year. Coinsurance (a percentage) falls with the price; a flat copay may not change at all.
- Out-of-pocket costs for Part D drugs are capped each year ($2,100 in 2026), whatever the drug.
- If you don't have Medicare, the negotiated price doesn't apply to you - check the fair cash price above instead.
Supply status: shortages & recalls
Recalls
A recall names specific lots. Check the lot number on your package against the recall before you worry - and don't stop a medicine without asking your pharmacist. What to do if your medication is recalled.
What people paid for Metformin / sitagliptin
Bought it recently? Share the price, the pharmacy and how you paid - it's the most useful thing the next person can read.
Official label & what changed
These highlights do not include all the information needed to use SITAGLIPTIN AND METFORMIN HYDROCHLORIDE TABLETS safely and effectively. See full prescribing information for SITAGLIPTIN AND METFORMIN HYDROCHLORIDE TABLETS. SITAGLIPTIN AND METFORMIN HYDROCHLORIDE tablets for oral use.Initial U.S. Approval: 2007
WARNING: LACTIC ACIDOSIS
Postmarketing cases of metformin-associated lactic acidosis have resulted in death, hypothermia, hypotension, and resistant bradyarrhythmias. The onset of metformin-associated lactic acidosis is often subtle, accompanied only by nonspecific symptoms such as malaise, myalgias, respiratory distress, somnolence, and abdominal pain. Metformin-associated lactic acidosis was characterized by elevated blood lactate levels (>5 mmol/Liter), anion gap acidosis (without evidence of ketonuria or ketonemia), an increased lactate/pyruvate ratio, and metformin plasma levels generally >5 mcg/mL [see Warnings and Precautions (5.1)].
Risk factors for metformin-associated lactic acidosis include renal impairment, concomitant use of certain drugs (e.g., carbonic anhydrase inhibitors such as topiramate), age 65 years old or greater, having a radiological study with contrast, surgery and other procedures, hypoxic states (e.g., acute congestive heart failure), excessive alcohol intake, hepatic impairment, and mitochondrial diseases [see Warnings and Precautions (5.1)].
Steps to reduce the risk of and manage metformin-associated lactic acidosis in these high risk groups are provided in the full prescribing information [see Dosage and Administration (2.2), Contraindications (4), Warnings and Precautions (5.1), Drug Interactions (7), and Use in Specific Populations (8.6, 8.7)].
If metformin-associated lactic acidosis is suspected, immediately discontinue sitagliptin and metformin hydrochloride tablets and institute general supportive measures in a hospital setting. Prompt hemodialysis is recommended [see Warnings and Precautions (5.1)].
WARNING: LACTIC ACIDOSIS
See full prescribing information for complete boxed warning.
• Postmarketing cases of metformin-associated lactic acidosis have resulted in death, hypothermia, hypotension, and resistant bradyarrhythmias. Symptoms included malaise, myalgias, respiratory distress, somnolence, and abdominal pain. Laboratory abnormalities included elevated blood lactate levels, anion gap acidosis, increased lactate/pyruvate ratio, and metformin plasma levels generally >5 mcg/mL. (5.1)
• Risk factors include renal impairment, concomitant use of certain drugs, age ≥65 years old, radiological studies with contrast, surgery and other procedures, hypoxic states, excessive alcohol intake, hepatic impairment, and mitochondrial diseases. Steps to reduce the risk of and manage metformin-associated lactic acidosis in these high-risk groups are provided in the Full Prescribing Information. (5.1)
• If lactic acidosis is suspected, discontinue sitagliptin and metformin hydrochloride tablets and institute general supportive measures in a hospital setting. Prompt hemodialysis is recommended. (5.1)
Recent major changes (as listed on the label)
Boxed Warning 8/2026
Warnings and Precautions, Lactic Acidosis (5.1) 8/2026
We check this label every day. When it changes, the sections that changed appear here, old text beside new.
We show the official text and what changed; we don't interpret it. Ask your pharmacist or prescriber what a change means for you.
Approval, patents & generics
- Application
- NDA216778 · Zydus Lifesciences
- First approved
- July 18, 2024 (2 years ago)
- Latest approved change
- August 11, 2026
- Approved label
- PDF, Sep 11, 2026
- Generic makers
- 3 approved generic applications on the market
Metformin / sitagliptin questions
How much does metformin / sitagliptin cost without insurance?
Pharmacies pay about $75.28 for 30 tablets of metformin / sitagliptin 1000 mg / 50 mg tablet ($2.51 per tablet). A fair cash price - that cost plus a 15% margin and a typical dispensing fee - is about $97.07. If you're quoted much more, check your quote and ask for the pharmacy's cash price.
What is the brand name of metformin / sitagliptin?
Is metformin / sitagliptin in shortage?
No shortage is reported for metformin / sitagliptin right now. We check the national shortage list every day.
Has metformin / sitagliptin been recalled?
1 recall on record, none ongoing. Recalls name specific lots - check yours.
When did the metformin / sitagliptin label last change?
The official label was last updated on October 12, 2026 (version 2). See what changed.
Does Medicare have a negotiated price for Metformin / sitagliptin?
Yes: $80.00 for a 30-day supply of Janumet / Janumet XR, from January 1, 2027. What you pay still depends on your plan.
Talk about metformin / sitagliptin
No comments yet. Questions, tips, what worked for you - start the conversation.